活血通络散治疗冠心病PCI术后心绞痛疗效研究
|
摘要
目的:观察活血通络散应用于冠心病经皮冠状动脉介入(PCI)术后心绞痛治疗中的疗效。方法:选取PCI治疗后发生心绞痛的96例冠心病患者纳入研究,分为两组,其中对照组予以单纯常规西药治疗,观察组在此基础上应用活血通络散进行治疗;治疗1个疗程后,对比两组患者心绞痛与心电图临床疗效,统计两组心绞痛发生时间、每次持续时间,同时观察两组患者治疗前后心功能、血清标志物表达水平、心肌肌钙蛋白I(cTnI)水平的变化情况。结果:观察组心绞痛与心电图的临床总有效率依次为91.67%、87.50%,对照组依次为60.42%、56.25%,两组对比,观察组效果更好(P<0.05);治疗后,两组患者心绞痛发作情况、心功能指标、各项血清标志物水平与本组治疗前对比可见统计学意义(P<0.05),且两组对比观察组效果更好(P<0.05)。结论:活血通络散应用于冠心病PCI术后心绞痛治疗中,能够有效提高患者心绞痛与心电图临床疗效,降低心绞痛发作频率与时间,改善患者心功能并降低血清标志物与心肌酶学指标的表达水平。
Objective:To observe the efficacy of Huoxue Tongluo powder in the treatment of angina pectoris after percutaneous coronary intervention(PCI).Methods:96 patients with coronary heart disease who developed angina pectoris after receiving PCI treatment were selected as the observation data.All the selected patients were randomly divided into control group and observation group,the control group was given conventional treatment,and the observation group was treated with Huoxue Tongluo powder designed on the basis of the treatment of the control group;after one course of treatment,the clinical effects of angina pectoris and electrocardiogram in the two groups were compared,and the time and duration of angina pectoris in the two groups were counted,and the changes of cardiac function,serum marker expression level,and myocardial troponin I(cTnI) level in the two groups before and after treatment were observed.Results:The total clinical effective rate of angina pectoris in the observation group was 91.67%,and the total clinical effective rate of electrocardiogram was 87.50%,and that in the control group was 60.42%and 56.25%,respectively;after treatment,angina attack,cardiac function indexes and expression levels of various serum markers in the two groups were improved compared with those before treatment(P<0.05),and the observation group was superior to the control group(P<0.05).Conclusion:The application of Huoxue Tongluo powder in the treatment of angina after PCI of coronary heart disease can effectively improve the clinical efficacy of angina and electrocardiogram,reduce the frequency and time of angina attack,improve the cardiac function of patients and reduce the expression level of serum markers and myocardial enzymes.
Objective:To observe the efficacy of Huoxue Tongluo powder in the treatment of angina pectoris after percutaneous coronary intervention(PCI).Methods:96 patients with coronary heart disease who developed angina pectoris after receiving PCI treatment were selected as the observation data.All the selected patients were randomly divided into control group and observation group,the control group was given conventional treatment,and the observation group was treated with Huoxue Tongluo powder designed on the basis of the treatment of the control group;after one course of treatment,the clinical effects of angina pectoris and electrocardiogram in the two groups were compared,and the time and duration of angina pectoris in the two groups were counted,and the changes of cardiac function,serum marker expression level,and myocardial troponin I(cTnI) level in the two groups before and after treatment were observed.Results:The total clinical effective rate of angina pectoris in the observation group was 91.67%,and the total clinical effective rate of electrocardiogram was 87.50%,and that in the control group was 60.42%and 56.25%,respectively;after treatment,angina attack,cardiac function indexes and expression levels of various serum markers in the two groups were improved compared with those before treatment(P<0.05),and the observation group was superior to the control group(P<0.05).Conclusion:The application of Huoxue Tongluo powder in the treatment of angina after PCI of coronary heart disease can effectively improve the clinical efficacy of angina and electrocardiogram,reduce the frequency and time of angina attack,improve the cardiac function of patients and reduce the expression level of serum markers and myocardial enzymes.
引文
[1] 张克清,戴珍,贾海莲.祛瘀化痰宁心汤联合西药治疗急性冠脉综合征经皮冠状动脉介入术后心绞痛45例临床观察[J].中医杂志,2018,59(22):1943-1947.
[2] 陈小卫,黄志文,田丽红,等.通心络胶囊对冠心病PCI术后心绞痛患者的疗效及炎性反应和血管内皮功能的影响[J].中国新药杂志,2017,26(20):2459-2462.
[3] Szalewska D,Tomaszewski J,Kusiak-Kaczmarek M,et al.Influence of ahybrid form of cardiac rehabilitation on exercise tolerance in coronary ar-tery disease patients with and without diabetes[J].Kardiol Pol,2015,73(9):753-60.
[4] Acharjee S,Teo KK,Jacobs AK,et al.Optimal medical therapywith or without percutaneous coronary intervention in womenwith stable coronary disease:apre-specified subset analysis of the clinical outcomes utilizing revascularization and Aggressive Drug Evaluation(COURAGE)trial[J].American Heart Journal,2016,173(10):108-117.
[5] 张迎,张敏,宁小康.尼可地尔对PCI术后再发不稳定型心绞痛患者的临床观察[J].陕西医学杂志,2015,44(6):749-751.
[6] 李金宝,杨国华,黄超联,等.四参护心汤治疗PCI术后心绞痛的疗效观察[J].中国中医急症,2018,27(11):1993-1996.
[7] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.不稳定性心绞痛和非ST段抬高心肌梗死诊断与治疗指南[J].中华心血管病杂志,2007,35(4):295-304.
[8] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.急性ST段抬高型心肌梗死诊断和治疗指南[J].中华心血管病杂志,2015,45(5):380-393.
[9] 中华人民共和国卫生部.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:68-73.
[10] 中华人民共和国卫生部医政司.中国常见心脑血管疾病诊治指南[M].北京:科学出版社,2000:59-60.
[11] 杨金龙,丁书文,姚晓东,等.益气活血解毒方联合西药治疗经皮冠状动脉介入治疗术后心绞痛患者46例临床观察[J].中医杂志,2017,25(10):850-853.
[12] 涂晓文,黄国明,王洪如,等.介入治疗冠心病患者冠状动脉搭桥术后再发心绞痛的近期疗效[J].中国老年学杂志,2015,35(23):6743-6744.
[13] 石磊,刘果果,杨坚毅.补阳还五汤加味治疗冠心病PCI术后气虚血瘀证临床观察[J].陕西中医,2017,38(9):1157-1159.
[14] 左可方,周李波,黄斌.自拟冠心舒方治疗冠心病PCI术后心绞痛的临床观察[J].湖北中医杂志,2015,23(9):33-34.
[15] 丁志欣.血府逐瘀汤对冠心病PCI术后病人心功能、炎症因子及不良事件发生率的影响[J].中西医结合心脑血管病杂志,2018,16(24):3648-3650.
[2] 陈小卫,黄志文,田丽红,等.通心络胶囊对冠心病PCI术后心绞痛患者的疗效及炎性反应和血管内皮功能的影响[J].中国新药杂志,2017,26(20):2459-2462.
[3] Szalewska D,Tomaszewski J,Kusiak-Kaczmarek M,et al.Influence of ahybrid form of cardiac rehabilitation on exercise tolerance in coronary ar-tery disease patients with and without diabetes[J].Kardiol Pol,2015,73(9):753-60.
[4] Acharjee S,Teo KK,Jacobs AK,et al.Optimal medical therapywith or without percutaneous coronary intervention in womenwith stable coronary disease:apre-specified subset analysis of the clinical outcomes utilizing revascularization and Aggressive Drug Evaluation(COURAGE)trial[J].American Heart Journal,2016,173(10):108-117.
[5] 张迎,张敏,宁小康.尼可地尔对PCI术后再发不稳定型心绞痛患者的临床观察[J].陕西医学杂志,2015,44(6):749-751.
[6] 李金宝,杨国华,黄超联,等.四参护心汤治疗PCI术后心绞痛的疗效观察[J].中国中医急症,2018,27(11):1993-1996.
[7] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.不稳定性心绞痛和非ST段抬高心肌梗死诊断与治疗指南[J].中华心血管病杂志,2007,35(4):295-304.
[8] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.急性ST段抬高型心肌梗死诊断和治疗指南[J].中华心血管病杂志,2015,45(5):380-393.
[9] 中华人民共和国卫生部.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:68-73.
[10] 中华人民共和国卫生部医政司.中国常见心脑血管疾病诊治指南[M].北京:科学出版社,2000:59-60.
[11] 杨金龙,丁书文,姚晓东,等.益气活血解毒方联合西药治疗经皮冠状动脉介入治疗术后心绞痛患者46例临床观察[J].中医杂志,2017,25(10):850-853.
[12] 涂晓文,黄国明,王洪如,等.介入治疗冠心病患者冠状动脉搭桥术后再发心绞痛的近期疗效[J].中国老年学杂志,2015,35(23):6743-6744.
[13] 石磊,刘果果,杨坚毅.补阳还五汤加味治疗冠心病PCI术后气虚血瘀证临床观察[J].陕西中医,2017,38(9):1157-1159.
[14] 左可方,周李波,黄斌.自拟冠心舒方治疗冠心病PCI术后心绞痛的临床观察[J].湖北中医杂志,2015,23(9):33-34.
[15] 丁志欣.血府逐瘀汤对冠心病PCI术后病人心功能、炎症因子及不良事件发生率的影响[J].中西医结合心脑血管病杂志,2018,16(24):3648-3650.